Artificial heart to give new hope to heart failure patients
A revolutionary, implantable mechanical device to be tested at The Alfred is set to provide new hope to patients with debilitating heart failure.
Visitor information – Everything you need to know about visiting our sites.
Many patients with high blood pressure try to follow a healthy diet, exercise, and take medications — yet their blood pressure is still high.
A/Prof Walton is coordinating the SPYRAL Hypertension study, a multi-centre, international, randomised, interventional study, using renal denervation. The purpose of the Trial is to provide information about the safety and efficacy of the investigational Symplicity Spyral™ catheter and the Symplicity G3™ generator to help reduce blood pressure. To be eligible for the Trial, patients must be between the ages of 20 and 80 and have uncontrolled hypertension, with readings of 150-180/90mmHg.
Dr Tony Walton is Deputy Director and Head of Catheter Laboratory in the Department of Cardiology. He is a clinician, interventional cardiologist who specialises in structural heart procedures.
Associate Professor Ingrid Hopper is a consultant physician at Alfred Health.
A revolutionary, implantable mechanical device to be tested at The Alfred is set to provide new hope to patients with debilitating heart failure.
Heart patients of the future are set to benefit from a new partnership which will bring together the combined strengths of three leading institutions in cardiovascular research and patient care.
When 43-year-old Melbourne dad Mark Wohlers suffered a cardiac arrest last year, it was the swift emergency response and an Australian-first clinical trial that gave him a second chance at life.